Global Genome Editing Market 2022-2028

Description

List of Tables

Global Genome editing Market Size, Share & Trends Analysis Report By Technology (Crispr-Based Genome Editing, Talen-Based Genome Editing, Zinc Finger Nucleases And Other) By application (Cell Line Engineering, Genetic Engineering, And Other Applications) By End user (Biotechnology & Pharmaceutical Companies, Research Institutes, And Others) Forecast 202-2028

The global genome editingmarket is anticipated to grow at a substantial CAGR of 20.1% during the forecast period.Genome editing (also called gene editing) is a group of technologies that give scientists the ability to change an organism's DNA. These technologies allow genetic material to be added, removed, or altered at particular locations in the genome. The growing infectious diseases is significantly growing the global genonme editing market.Currently, genome editing is used in cells and animal models in research labs to understand diseases. It is being explored in research and clinical trials for a wide variety of diseases, including single-gene disorders such as cystic fibrosis, hemophilia, and sickle cell disease. It also holds promise for the treatment and prevention of more complex diseases, such as cancer, heart disease, mental illness, and human immunodeficiency virus (HIV) infection. For instance, according to WHO, 37.7 million people were living with HIV in 2020, and over two-thirds of them nearly 25.4 million are in the African region. In 2020, 6,80,000 people died from HIV-related causes and 1.5 million acquired HIV. Owing to the rising number of diseases such as cancer, HIV, chronic diseases, is expected to drive the growth of the global genome editing market.

The global genome editing market is segmented based on technology, application and end-user. Based on technology the market is segmented intocrispr-based genome editing, talen-based genome editing, zinc finger nucleases and other. Based on application the market is segmeted into cell line engineering, genetic engineering, and other applications.Based on end user the market is segmented into biotechnology & pharmaceutical companies, contract research organizations, research institutes and others

On the basis of application, the cell line engineering segment isanticipated to grow at the fastest rate, as the CRISPR technology is widely being used to increase the productivity of CHO cell lines. Cell lines have transformed scientific research, they are used for vaccine production, testing drug metabolism and cytotoxicity, antibody production, study of gene function, generation of artificial tissues (e.g., artificial skin) and synthesis of biological compounds e.g., therapeutic proteins. These factors acts as driver for the global genome editing market.

Geographically market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America dominates the market and is expected to continue its presence over the forecast period. The growth can be attributed to the increasing number of cancer patients and increasing adoption of genome editing solutions in cancer.Since cancer is caused by genomic changes in tumor cells, CRISPR/Cas9 can be used in the field of cancer research to edit genomes for exploration of the mechanisms of tumorigenesis and development

The major companies serving the global genome editingmarket are HORIZON DISCOVERY GROUP, Editas Medicine , Tecan Life Sciencesand others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in 2020, ERS Genomics and Applied StemCell, Inc. signed an agreement for the commercialization of genome editing services.

Research Methodology

The market study of the global genome editingmarket is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.
Whitepapers, researchpapers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Genome editingMarket Research and Analysis by Technology

2. Global Genome editingMarket Research and Analysis by Application

3. Global Genome editingMarket Research and Analysis by End-User

The Report Covers

Comprehensive research methodology of the globalgenome editing market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global genome editingmarket.
Insights about market determinants that are stimulating the global genome editingmarket.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2018285

Category-Biotechnology

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the GlobalGenome editingMarket
Recovery Scenario of GlobalGenome editingMarket
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. BY Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key CompanyAnalysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Ananlysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. GlobalGenome EditingMarket, by Technologies
- 4.1.1. Crispr-Based Genome Editing
- 4.1.2. Talen-Based Genome Editing
- 4.1.3. Zinc Finger Nucleases
- 4.1.4. Other
4.2. Global Genome EditingMarket, by Application
- 4.2.1. Cell line Engineering
- 4.2.2. Genetic eEngineering
  - 4.2.2.1. Plant genetic Engineering
  - 4.2.2.2. Animal genetic Engineering
- 4.2.3. Other
4.3. Global Genome Editing Market, by End-Users
- 4.3.1. Biotechnology & pharmaceutical companies
- 4.3.2. Contract Research Organizations
- 4.3.3. Research Institutes
- 4.3.4. Others

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Benchling, Inc.
6.2. Biogen Inc.
6.3. Caribou Biosciences, Inc.
6.4. Crispr Therapeutics Inc.
6.5. Editas Medicine
6.6. Editas Medicine Inc.
6.7. Egenesis Bio
6.8. Genscript
6.9. Horizon Discovery Group
6.10. Integrated DNAna Technologies, Inc.
6.11. Intellia Therapeutics, Inc.
6.12. Kadmon Holdings, Inc.
6.13. Lonza
6.14. Merck Kgaa
6.15. New England Biolabs
6.16. Origene Technologies, Inc.
6.17. Poseida Therapeutics, Inc.
6.18. Sangamo Therapeutics, Inc.
6.19. Synthego Corp
6.20. Thermo Fisher Scientific, Inc.
6.21. Transposagen Biopharmaceuticals Inc.
6.22. Vertex Pharmaceuticals
6.23. Vir Biotechnology
6.24. Voyager Therapeutics, Inc.